Edward M. Scolnick
| Edward Scolnick | |
|---|---|
| Institutions | |
| Alma mater | |
| Known for | Discovery of RAS pathway |
Edward Scolnick is a core investigator at the Broad Institute, the former founding director of the Stanley Center for Psychiatric Research at Broad Institute, and former head of research and development at Merck Research Laboratories.
Scolnick earned a BA in 1961 from Harvard University and an MD in 1965 from Harvard Medical School. After medical school, he joined the Public Health Service to avoid being drafted into the Vietnam War. During his 15 years at the NIH's National Cancer Institute, Scolnick discovered the RAS oncogene that is involved in the critical signaling pathway that shifts an otherwise normal cell into the aggressive cells known as tumor cells. His work helped establish the concept of blocking signaling pathways as fundamental to cancer biology and drug discovery.
Scolnick joined Merck in 1982 as executive director of virus and cell biology, after being recruited from the National Institutes of Health. He was head of Research at Merck Research Laboratories from 1985 until he stepped down in 2002. While at Merck, he was involved in the development and introduction of 29 new medications and vaccines.
He was a key figure in the development and marketing of Vioxx, which was pulled from the market after it was discovered that the drug caused a dangerously high risk of myocardial infarction. Legal claims resulting from this has cost Merck billions. During the 5 years it was available in the US, more than 38,000 deaths were related to Vioxx use, and up to 25 million Americans had taken the drug. In the subsequent investigations, it was revealed that it was likely that Merck knew about the adverse effects of the drug, and Scolnick had dismissed them in order to push the drug to market before Bayer's Celebrex.
...
Wikipedia